RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period

Trial Profile

RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Venous thrombosis
  • Focus Therapeutic Use
  • Acronyms RE-SPECT CVT
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 03 Oct 2017 Planned End Date changed from 19 May 2018 to 27 Jun 2018.
    • 03 Oct 2017 Planned primary completion date changed from 5 May 2018 to 27 Jun 2018.
    • 30 May 2017 Planned End Date changed from 20 Apr 2018 to 19 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top